Logotipo de Valence
populares
Iniciar sesión
Loading data for ANRO — first visit, this takes a few seconds.

Añadir a la lista de seguimiento

Alto Neuroscience Inc.

NYSE: ANRO · Precio en tiempo real · USD
34.26
+0.13 (0.38%)
Al cierre: Aug 19, 2026, 3:59 PM
34.21
-1.95%
Fuera de horario: 7:56 PM

Alto Neuroscience Inc. (ANRO) Stock Price, Analysis & Data

0.38%
Precio de compra34.16
Capitalización de mercado1.37B
Ingresos (TTM)n/a
Beneficio neto (TTM)-84.24M
Beta1.09
EPS (TTM)-2.32
Ratio PER (TTM)n/a
Adelante PE-10.62
P/B (TTM)5.59
P/S (TTM)n/a
Earnings DateNov 11, 2026
Precio de venta34.43
Volumen129,759
Volumen medio (20D)521,974
Abierto35.00
Anterior Cerrar34.13
Rango del día33.80 - 35.34
Rango de 52 semanas3.32 - 35.34
analistan/a
Precio objetivon/a
Dividendosn/a
Fecha ex dividendon/a

Acerca de ANRO

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive d...

[Leer más]
Industria Biotechnology
Sector Healthcare
IPO Fecha Feb 2, 2024
Empleados 68
Bolsa de Valores NYSE
Símbolo bursátil ANRO
Sitio web https://www.altoneuroscience.com
Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de Alto Neuroscience fueron 0, un aumento de undefined% en comparación con 0 del año anterior. Las ganancias fueron -63.24M, un aumento de 2.94%.

Estados financieros

Sorpresa de resultados

Alto Neuroscience ha publicado sus resultados trimestrales en Aug 12, 2026:
  • Ingresos de $0 falla las estimaciones por $0, con NaN% Crecimiento interanual.
  • EPS de -0.65 supera las estimaciones en 0.12, con 0.00% Crecimiento interanual.

    • Próxima publicación de resultados

    Está previsto que Alto Neuroscience Inc. publique sus resultados el Nov 11, 2026, durante el horario de mercado.
    Los analistas proyectan ingresos de ... Actualizar
    news image

    3 días hace · Simply Wall St.

    Alto Neuroscience (ANRO) Reports Another Quarterly Loss, Is The Stock Already Overvalued?

    Alto Neuroscience (ANRO) is back in focus after reporting second quarter 2026 results. The company reported a net loss of US$27.64 million and a basic loss per share from continuing operations of US$0...

    news image

    3 días hace · Simply Wall St.

    Are Alto Neuroscience’s (ANRO) Rising Losses Funding a Stronger Depression Pipeline or Diluting Discipline?

    Alto Neuroscience, Inc. reported its second-quarter and first-half 2026 results, recording a wider net loss of US$27.64 million for Q2 and US$53.88 million for the six months ended June 30, 2026, with...

    news image

    3 días hace · Simply Wall St.

    Alto Neuroscience (ANRO) Stock Looks Stretched On Expanded ALTO 207 Plans

    Alto Neuroscience stock has delivered a very large gain over the past year, yet the valuation checks currently lean toward the shares looking expensive rather than like a clear bargain. Over the last ...

    news image

    1 mes hace · Insider Monkey

    Is Alto Neuroscience, Inc. (ANRO) Stock Positioned for Growth With New Insights Into Anhedonia Treatment?

    We recently compiled a list of the 8 Best Up and Coming Pharmaceutical Stocks to Buy Now. Alto Neuroscience, Inc. (NYSE:ANRO) is one of the best up and coming stocks on our list. On June 15, ALTO high...

    news image

    2 meses hace · Motley Fool

    Alpha Wave Global Initiates COPT Defense Properties Position, According to Recent SEC Filing

    COPT Defense Properties serves defense and intelligence tenants near secure government hubs. Investors will be closely watching whether that niche can keep supporting growth while much of the office m...

    Página 1 de 2